Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
07/2014
07/01/2014US8765133 Method of producing anti-CD166 antibody in ostrich
07/01/2014US8765132 Human cytomegalovirus neutralizing antibodies and use thereof
07/01/2014US8765131 Methods of inhibiting alternative pathway complement activation with anti-factor D antibodies
07/01/2014US8765130 Antagonistic DR3 ligands
07/01/2014US8765129 Anti-hepcidin antibodies and uses thereof
07/01/2014US8765128 Anti-cMET antibody
07/01/2014US8765127 Methods of preventing ischemia/reperfusion damage to kidney using antibodies that bind BMP-1 isoforms
07/01/2014US8765126 Methods of treating complications and disorders associated with G-CSF administration
07/01/2014US8765125 Methods of treating autoimmune diseases with Dll4 antagonists
07/01/2014US8765124 Stabilized preparation containing protein
07/01/2014US8765075 Immunoassay reagent composition
06/2014
06/30/2014CA2800117A1 Personal vaccine for hiv and any other virus, for people and animals
06/26/2014WO2014100760A2 Antibodies for modulating binding between lrp and wise
06/26/2014WO2014100746A2 Tspan 33 is a candidate for antibody targeted therapy for the treatment of b cell hodgkin lymphomas
06/26/2014WO2014100740A1 Anti-ntb-a antibodies and related compositions and methods
06/26/2014WO2014100689A1 Anti-gdf15 antibodies
06/26/2014WO2014100565A1 Methods and compositions relating to treatment of cancer
06/26/2014WO2014100490A1 Multivalent antibody analogs, and methods of their preparation and use
06/26/2014WO2014100483A1 Anti-human b7-h4 antibodies and their uses
06/26/2014WO2014100443A2 Methods of producing immunoconjugates
06/26/2014WO2014100439A2 B7-h4 specific antibodies, and compositions and methods of use thereof
06/26/2014WO2014100377A1 Mixed payload containing polymers and use therof
06/26/2014WO2014100143A2 Liquid antibody formulation with improved aggregation properties
06/26/2014WO2014100139A1 Glycan-modified anti-cd4 antibodies for hiv prevention and therapy
06/26/2014WO2014100014A1 Super-2 complexes with antibody to augment il-2 therapy
06/26/2014WO2014099931A1 Influenza virus vaccines and uses thereof
06/26/2014WO2014099908A1 Methods for inhibiting viral infection in transplant patients
06/26/2014WO2014099669A1 Porcine parvovirus 5a, methods of use and vaccine
06/26/2014WO2014099636A1 Liquid formulations for an anti-tnf alpha antibody
06/26/2014WO2014099391A1 Bmp-6 antibodies
06/26/2014WO2014098243A1 iPS/ES CELL-SPECIFIC ANTIBODY HAVING CYTOTOXICITY TO TARGET CELLS AND USE THEREOF
06/26/2014WO2014098012A1 Method for activating helper t cell
06/26/2014WO2014097762A1 Antibody to highly pathogenic avian influenza
06/26/2014WO2014097648A1 Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective
06/26/2014WO2014097154A1 A polyvalent combined immunising and/or therapeutic preparation for use in bacterial infections or food poisoning, particularly salmonellosis, a method for production of this preparation, its use and a vaccine comprising this preparation
06/26/2014WO2014096672A1 Use of monoclonal antibodies for the treatment of inflammation and bacterial infections
06/26/2014WO2014096393A1 Immunogenic composition comprising elements of c. difficile cdtb and/or cdta proteins
06/26/2014WO2014096321A1 Antibodies specific to tau phosphorylated at serine 422 and uses for the treatment and diagnosis of tauopathies
06/26/2014WO2014096311A1 Leptospira with increased antigenic mass
06/26/2014WO2014096070A1 A vaccine for treatment or prevention of burkholderia infection in a mammal
06/26/2014WO2014096051A1 Anti her2 antibody formulation
06/26/2014WO2014096013A1 Novel recombinant outer membrane proteins from brachyspira hyodysenteriae and uses thereof
06/26/2014WO2014095998A1 A method for preventing or treating an hiv infection
06/26/2014WO2014095944A1 Vaccine composition for use in immuno-compromised populations
06/26/2014WO2014095943A1 Vaccine composition for naive subjects
06/26/2014WO2014095916A1 Ninjurin-1 as therapeutic target for brain tumor
06/26/2014WO2014095866A1 Intranasal vaccination dosage regimen
06/26/2014WO2014095771A1 Conjugates for protecting against diphtheria and/or tetanus
06/26/2014WO2014095088A1 Egfr targeted therapy of neurological disorders and pain
06/26/2014WO2014094528A1 Compounds and methods for the treatment of cd20 positive diseases
06/26/2014WO2014094355A1 Compounds and methods for the treatment of egfr positive diseases
06/26/2014WO2014074797A8 Ultra low density pulmonary powders
06/26/2014WO2014074532A3 Compositions and methods for modulating cell signaling
06/26/2014WO2014071074A3 Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
06/26/2014WO2014067011A8 Crystal structures of heterodimeric fc domains
06/26/2014WO2014064526A3 Methylation of dcr1 as predictive marker for drug response
06/26/2014WO2014039994A3 Targeting chemotherapy agent resistance in cancer
06/26/2014WO2014039903A3 Stable aqueous formulations of adalimumab
06/26/2014WO2014036345A3 Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins
06/26/2014WO2014003821A9 Methods and compositions for segregating target nucleic acid from mixed nucleic acid samples
06/26/2014WO2013103816A8 Partial mhc constructs and methods of use
06/26/2014WO2009035791A9 Lox and l0xl2 inhibitors and uses thereof
06/26/2014US20140179903 High Affinity Human Antibodies to Human Protease-Activated Receptor 2
06/26/2014US20140179877 Macromolecule conjugate
06/26/2014US20140179596 Albumin fusion proteins
06/26/2014US20140178969 Viral purification methods
06/26/2014US20140178966 Animal product free system and process for purifying a botulinum toxin
06/26/2014US20140178482 Method of producing virus-like particles of picornavirus using a small-ubiquitin-related modifier fusion protein expression system
06/26/2014US20140178478 Immuno-Adjuvant Emulsion
06/26/2014US20140178476 Highly Efficient Delivery of a Large Therapeutic Mass Aerosol
06/26/2014US20140178474 Selective local inhibition of tnfr1-mediated functions at the site of antigen/allergen presentation
06/26/2014US20140178437 Use of a food additive based on at least one phytonutrient for stimulating vaccine immunity against apicomplexa in animals
06/26/2014US20140178435 Vaccine comprising inactivated cells of haemophilus parasuis bacteria of serotype 5
06/26/2014US20140178434 Method and compositions
06/26/2014US20140178433 Leptospira with increased antigenic mass
06/26/2014US20140178431 Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines
06/26/2014US20140178430 Idna vaccines and methods for using the same
06/26/2014US20140178429 Vaccines Including Antigen From Four Strains of Influenza Virus
06/26/2014US20140178428 Quality control methods for oil-in-water emulsions containing squalene
06/26/2014US20140178427 Total polysaccharides of radix isatidis and their fractions, and uses thereof as vaccine adjuvants
06/26/2014US20140178426 Nucleic Acid Composition and Methods of Eliciting an Immune Response Using the Same
06/26/2014US20140178425 Compositions for immunising against staphylococcus aureus
06/26/2014US20140178423 Novel compositions and methods
06/26/2014US20140178422 Primary mesenchymal stem cells as a vaccine platform
06/26/2014US20140178421 Use of Native Peptides and Their Optimized Derivatives For Vaccination
06/26/2014US20140178419 Rabies glycoprotein virus-like particles (vlps)
06/26/2014US20140178418 Breast Cancer Vaccine
06/26/2014US20140178408 Method of producing an antibody
06/26/2014US20140178407 Methods and Compositions for Treating Conditions of the Eye
06/26/2014US20140178406 Use of goat serum for veterinary treatment
06/26/2014US20140178403 Method of inhibiting binding or activity of mif by administering a mif antagonist
06/26/2014US20140178402 Pharmaceutical compositions comprising human antibodies to pcsk9
06/26/2014US20140178400 T-Helper Cell Type 17 Lineage-Specific Adjuvants, Compositions and Methods
06/26/2014US20140178397 Anti-angiogenic therapy
06/26/2014US20140178396 Treatment of cardiovascular diseases
06/26/2014US20140178395 Treatment of nephropathy
06/26/2014US20140178392 Nogo Receptor-Mediated Blockade of Axonal Growth
06/26/2014US20140178383 Stable formulations of polypeptides and uses thereof
06/26/2014US20140178373 Pharmaceutical composition for treatment and/or prophylaxis of cancer
06/26/2014US20140178372 Methods of treating hematologic cancers
1 ... 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 ... 1823